|Videos|July 24, 2023
Safety Profile of S1P Receptor Modulators for Multiple Sclerosis
Author(s)Krzysztof Selmaj, MD, PhD
Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).
Advertisement
Episodes in this series
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Here's some of what is coming soon to NeurologyLive® this week.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5